文献速递肿瘤 PET/CT

68Ga-FAPI PET/CT 在下消化道恶性肿瘤患者中的作用:首次临床经验

The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience.
PubMed 文献 · J Nucl Med · 2020-02-14

本研究对22例下消化道肿瘤患者行68Ga-FAPI PET/CT,其中15例转移性疾病、1例疑似局部复发、6例初治。肝转移和肛癌摄取最高,SUVmax分别为9.1和13.9;初治患者中50%的TNM分期发生改变,转移患者中47%出现新发现,FAPI显像对肿瘤或放疗管理造成高、中、低程度改变的比例分别为19%、33%、29%。

要点

  • 68Ga-FAPI PET/CT可可靠检测下消化道原发和转移性肿瘤。
  • 初治患者中50%的TNM分期发生改变,转移患者中47%出现新发现。
  • FAPI显像对肿瘤或放疗管理造成高、中、低程度改变的比例分别为19%、33%、29%。

核心结论

  • 68Ga-FAPI PET/CT可可靠检测下消化道原发和转移性肿瘤,并导致TNM状态及肿瘤或放疗管理发生相关改变。
  • 68Ga-FAPI PET/CT似乎是用于下消化道肿瘤诊断和管理的高度有前景的显像剂,可能为肿瘤分期或再分期开辟新应用。

研究设计与样本

  • 本研究为首次临床分析,纳入22例下消化道肿瘤患者,包括15例转移性疾病、1例疑似局部复发和6例初治患者,行68Ga-FAPI PET/CT。
  • 对68Ga-FAPI-04和68Ga-FAPI-46的摄取采用SUVmax和SUVmean进行量化。
  • 与标准影像比较后,记录肿瘤分期或定位以及肿瘤或放疗管理的变化。

主要发现

  • FAPI示踪剂最高摄取见于肝转移和肛癌,SUVmax分别为9.1和13.9。
  • 由于正常组织本底活性低,大多数病灶的肿瘤与本底比值高于3。
  • 初治患者中TNM分期改变者为50%,转移患者中新发现出现者为47%。
  • FAPI显像对肿瘤或放疗管理造成高、中、低程度改变的比例分别为19%、33%、29%。
  • 几乎所有接受照射的患者,68Ga-FAPI PET/CT均改善了靶区勾画。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For oncologic management or radiotherapy planning, reliable staging tools are essential. The recent development of quinoline-based ligands targeting cancer-associated fibroblasts demonstrated promising preclinical and clinical results. The current study aimed to evaluate the role of fibroblast activation protein inhibitor (FAPI) PET/CT as a first clinical analysis for primary malignancies within the lower gastrointestinal tract (LGT). Methods:68Ga-FAPI PET/CT was performed on a cohort of 22 patients with LGT tumors, including 15 patients with metastatic disease, 1 patient with suspected local relapse, and 6 treatment-naïve patients. Uptake of 68Ga-FAPI-04 and 68Ga-FAPI-46 was quantified by SUVmax and SUVmean After comparison with standard imaging, changes in tumor stage or localization and in oncologic or radiooncologic management were recorded. Results: The highest uptake of FAPI tracer was observed in liver metastases and anal cancer, with an SUVmax of 9.1 and 13.9, respectively. Because of low background activity in normal tissue, there was a high tumor-to-background ratio of more than 3 in most lesions. In treatment-naïve patients, TNM was changed in 50%, whereas in patients with metastases, new findings occurred in 47%. In total, FAPI imaging caused a high, medium, and low change in oncologic or radiooncologic management in 19%, 33%, and 29%, respectively. For almost every patient undergoing irradiation, target volume delineation was improved by 68Ga-FAPI PET/CT. Conclusion: The present study demonstrated that both primary and metastatic LGT tumors were reliably detected by 68Ga-FAPI PET/CT, leading to relevant changes in TNM status and oncologic or radiooncologic management. 68Ga-FAPI PET/CT seems to be a highly promising imaging agent for the diagnosis and management of LGT tumors, potentially opening new applications for tumor staging or restaging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Koerber SA, Staudinger F, Kratochwil C, et al. The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. J Nucl Med. 2020. PMID: 32060216. doi:10.2967/jnumed.119.237016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。